ADAP - アダプティミュ―ン・セラピュ―ティクス （Adaptimmune Therapeutics plc） アダプティミュ―ン・セラピュ―ティクスADAPのチャート
ADAPの企業情報
| symbol | ADAP |
|---|---|
| 会社名 | Adaptimmune Therapeutics PLC （アダプティミュ―ン・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets find and genetically engineer TCR and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials which are directed to cancer testis antigens NY-ESO-1 MAGE-A4 and MAGE-A10. アダプティミュ―ン・セラピュ―ティクスは、英国のバイオ医薬品企業。独自のT細胞レセプタ―・プラットフォ―ムによる新しい癌免疫治療製品の開発に焦点を当て事業を展開。主な製品候補には、癌抗原として親和性が強化されたT細胞レセプタ―治療薬のNY-ESO-1およびNY-ESOがある。 adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page. |
| 本社所在地 | 60 Jubilee Avenue Milton Park Abingdon Oxfordshire OX14 4RY GBR |
| 代表者氏名 | James Julian Noble ジェームズジュリアンノーブル |
| 代表者役職名 | Chief Executive Officer Director 最高経営責任者（CEO） |
| 電話番号 | +44 1235-43-0000 |
| 設立年月日 | 41974 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 371人 |
| url | www.adaptimmune.com |
| nasdaq_url | https://www.nasdaq.com/symbol/adap |
| adr_tso | 66427089 |
| EBITDA | EBITDA（百万ドル） -84.89300 |
| 終値（lastsale） | 13.2 |
| 時価総額（marketcap） | 876837574.8 |
| 時価総額 | 時価総額（百万ドル） 1259.51 |
| 売上高 | 売上高（百万ドル） 48.68900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1130.482 |
| 当期純利益 | 当期純利益（百万ドル） -92.72400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Adaptimmune Therapeutics PLC - ADR revenues increased from $6.4M to $17.2M. Net loss increased 54% to $64.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 41% to $47.7M (expense) Other (expense) income net decrease from $3.7M (income) to $8.3M (expense). |
ADAPのテクニカル分析
ADAPのニュース
Adaptimmune Therapeutics PLC: Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company 2023/06/01 19:38:00 Finanz Nachrichten
First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023Compelling clinical data with late-stage programs targeting MAGE-A4 and mes…
Adaptimmune Therapeutics PLC: Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO 2023/05/25 21:02:00 Finanz Nachrichten
Approximately 39% of patients had clinical responses after a single dose of afami-cel in Cohort 1 of the pivotal SPEARHEAD-1 trial and the median duration of response was ~12 months (CTOS 2022)Med…
Adaptimmune Therapeutics plc (ADAP) Q1 2023 Earnings Call Transcript 2023/05/12 17:09:08 Seeking Alpha
Adaptimmune Therapeutics plc (NASDAQ:NASDAQ:ADAP) Q1 2023 Earnings Conference Call May 12, 2023 8:00 AM ETCompany ParticipantsJuli Miller - Head-Investor RelationsAdrian Rawcliffe - Chief…
Adaptimmune Therapeutics PLC: Adaptimmune Reports First Quarter Financial Results and Business Update 2023/05/12 11:38:00 Finanz Nachrichten
Completed submission of the clinical module (Part 2) of the afami-cel BLA; afami-cel is targeted to be the first marketed engineered T-cell therapy for a solid tumorAdaptimmune and GSK agreed term…
Recap: Adaptimmune Therapeutics Q1 Earnings 2023/05/12 11:35:16 Benzinga
Adaptimmune Therapeutics (NASDAQ: ADAP ) reported its Q1 earnings results on Friday, May 12, 2023 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Adaptimmune Therapeutics missed estimated earnings by 100.0%, reporting an EPS of $0.0 versus an … Full story available on Benzinga.com
Adaptimmune Therapeutics plc PT Lowered to $1.50 at Wells Fargo 2022/10/04 11:14:08 Investing.com
https://www.investing.com/news/pro/adaptimmune-therapeutics-plc-pt-lowered-to-150-at-wells-fargo-432SI-2904746
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adaptimmune Therapeutics plc - ADAP 2022/09/27 22:25:00 GlobeNewswire
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adaptimmune Therapeutics plc (“Adaptimmune” or the “Company”) (NASDAQ: ADAP). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
Sarcoma Foundation of America Honors Adaptimmune Therapeutics with 2022 Vision of Hope Award 2022/09/15 17:14:07 EIN News
The Sarcoma Foundation of America (SFA), an organization dedicated to increasing research and awareness for sarcoma, today announced that Adaptimmune
Adaptimmune Therapeutics (ADAP) Presents At ESMO Congress 2022 - Slideshow (NASDAQ:ADAP) 2022/09/15 16:55:16 Seeking Alpha
The following slide deck was published by Adaptimmune Therapeutics plc in conjunction with this event.
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2022 Results - Earnings Call Transcript 2022/08/07 03:39:02 Seeking Alpha
Adaptimmune Therapeutics plc (NASDAQ:NASDAQ:ADAP) Q2 2022 Earnings Conference Call Aug 4, 2022 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief…
Adaptimmune Therapeutics: Q2 Earnings Insights 2022/08/04 13:41:09 Benzinga
Adaptimmune Therapeutics (NASDAQ: ADAP ) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Adaptimmune Therapeutics beat estimated earnings by 80.0%, reporting an EPS of $-0.05 versus … Full story available on Benzinga.com
Adaptimmune Therapeutics Earnings Beat, Revenue Misses In Q2 By Investing.com 2022/08/04 13:08:00 Investing.com
Adaptimmune Therapeutics Earnings Beat, Revenue Misses In Q2
Adaptimmune Q2 2022 Earnings Preview (NASDAQ:ADAP) 2022/08/03 16:05:00 Seeking Alpha
Adaptimmune (ADAP) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open.The consensus EPS Estimate is -$0.29 (-625.0% Y/Y) and the consensus…
Adaptimmune Therapeutics PLC: Adaptimmune to Report Q2 2022 Financial Results and Business Updates on Thursday, August 4, 2022 2022/07/21 12:00:00 Finanz Nachrichten
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - July 21, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report fi…